Icon of the Instituts for Quality and Efficiency in Health Care

[A25-122] Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V

Last updated 02.01.2026

Project no.:
A25-122

Commission:
Commission awarded on 19.09.2025 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with resectable non-small cell lung cancer at high risk of recurrence, in combination with platinum-based chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A25-122

Project no. Title Status
A25-119 Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V Commission completed
A25-118 Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-131 Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-129 Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-128 Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V Commission completed
A24-127 Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V Commission completed
A24-126 Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V Commission completed
A24-130 Tislelizumab (oesophageal carcinoma, advanced, second line) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page